Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Novartis is still waiting for FDA approval of its  PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but is already planning a move the drug into the first-line se